Wealth Manager - the site for professional investment managers

Register to get unlimited access to all of Citywire’s Fund Manager database. Registration is free and only takes a minute.

Odey buys £70m stake in biotech new boy

Odey buys £70m stake in biotech new boy

Hedge fund luminary Crispin Odey's investment boutique snapped up a large interest in Circassia Pharmaceuticals upon its initial public offering on 13 March.

Odey (pictured) bought 22.5 million shares in Circassia – a stake worth almost £70 million and equivalent to 12% of the business.

According to a filing on the London Stock Exchange, the holding is spread across a number of funds, with Crispin's Odey European fund holding 3.79% and all other funds holding less than 3%.  

The flotation of Oxford-based Circassia was the biggest in the UK’s biotech sector for decades, and at an initial launch price of £3.10 valued the firm at the very top of the expected range.

Circassia specialises in the development of allergy therapies, and it plans to use the proceeds from the listing to roll out its cat allergy treatment and develop other products for grass and dust-mite allergies.

It lost £20 million in 2013, but is now valued at almost £600 million.

'This is a milestone achievement in Circassia's history which demonstrates the significant progress we have delivered over the past seven years,' Circassia chief executive Steven Harris told the stockmarket last week. 

He added: 'We have been met with an enthusiastic response from investors across the UK, US and EU who have recognised the significant potential of our product portfolio and platform technology.

'As a result, we now have funds to bring Cat-SPIRE to market; the first of a new generation of allergy immunotherapy products that have the potential to overcome the limitations of current treatments.'

Odey’s firm, which he launched in 1991, oversees more than £7 billion of assets.

Crispin Odey personally runs a range of funds, including the Odey Pan European fund and is + rated by Citywire.

According to Citywire data, the fund has returned 32.8% over the past three years, compared with an average of 25.8% from his peer group.

He is also a renowned shorter of stocks, and among others is currently betting against Manchester United and Sainsbury’s.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.
Citywire TV
Play JPM’s Negyal: Back divis to temper EM volatility

JPM’s Negyal: Back divis to temper EM volatility

Omar Negyal, co-manager of the JPMorgan Global Emerging Markets Income trust, says a dividend approach to emerging markets reduces the volatility of investing in the asset class.

Play WMR: Why Russia will lose this war

WMR: Why Russia will lose this war

Author and journalist Adam Lebor believes a perfect storm is brewing when it comes to the Russian economy. .

Play WMR: Gerard Lyons warns Asia is the real risk, not Russia & Ukraine

WMR: Gerard Lyons warns Asia is the real risk, not Russia & Ukraine

Chief economic adviser to London mayor Boris Johnson outlines the geo-political risks in Asia and explains why the risk of another eurozone crisis must not be underestimated.

Your Business: Cover Star Club

Profile: The adviser that tempted Robin Minter-Kemp on board

Profile: The adviser that tempted Robin Minter-Kemp on board

It is rare to meet an impassioned individual who is willing to bang the drum for investment advisory right now

Wealth Manager on Twitter